Tradestie Institutional Equity Comparison Engine

CRSP vs PACB โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CRSP Overall Edge

CRSP Captures Institutional Edge (3โ€“1 Pillars ยท 8โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CRISPR Therapeutics AG (CRSP) driven by superior Valuation, Growth & Margin, Options & Structure while PACB counters with relative strength in Momentum & Technical. Fundamentally, CRSP trades at 23.4x Forward P/E with -2058.6% operating margin (+1325.1% YoY revenue) versus PACB at N/M Forward P/E and -333.0% operating margin (+5.5% YoY). In options structure, CRSP sits in BREAKDOWN (52nd %ile IV; Dealer Gamma Walls on Pro) against PACB sits in BREAKDOWN (47th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CRSP
CRSP 23.4x vs PACB N/M Fwd P/E
Growth & Margin Winner CRSP
Op Margin -2058.6% vs -333.0% ยท YoY +1325.1% vs +5.5%
Momentum & Technical Winner PACB
1Y -20.5% vs +15.6% ยท 52W Pos 1% vs 34%
Options & Structure Winner CRSP
BREAKDOWN (52nd %ile IV) vs BREAKDOWN (47th %ile IV)
CRSP NASDAQ
CRISPR Therapeutics AG
Biological Products, (No Disgnostic Substances)
$40.61
-3.86% 1D
Market Cap $4.1B
1M Return -17.54%
1Y Return -20.54%
Forward P/E 23.4x
Unified AI Score
48.6 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 68.0 Mom 60.0
PACB NASDAQ
Pacific Biosciences of California, Inc.
Laboratory Analytical Instruments
$1.89
-3.83% 1D
Market Cap $615.1M
1M Return +8.96%
1Y Return +15.64%
Forward P/E N/M
Unified AI Score
38.0 / 100 SELL
Tech 15.0 Fund 35.0 Flow 57.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CRSP -20.54% PACB +15.64% Spread: +36.18 pp (PACB Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period CRSP Revenue PACB Revenue CRSP Op. Margin PACB Op. Margin Margin Edge
FY2018 $0M $80M -5087.8% -128.4% PACB
FY2019 $290M $90M 16.1% -110.6% CRSP
FY2020 $0M $80M -49295.5% -132.3% PACB
FY2021 $910M $130M 40.8% -161.2% CRSP
FY2022 $0M $130M -56190.4% -239.4% PACB
FY2023 $370M $200M -60.0% -166.8% CRSP
FY2024 $40M $150M -1250.4% -308.0% PACB
FY2025 $0M $160M -18933.6% -346.2% PACB

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CRSP (8) vs PACB (2)
Institutional Metric CRSP PACB Criterion Row Winner
Market Capitalization Scale $4.1B $615.1M Larger Scale CRSP
Trailing P/E Ratio Valuation 23.4x N/M Lower Multiple CRSP
Forward P/E Ratio Valuation 23.4x N/M Lower Multiple CRSP
Revenue Growth (YoY) Growth +1325.1% +5.5% Higher Growth CRSP
Operating Margin (TTM) Profitability -2058.6% -333.0% Higher Margin PACB
Net Profit Margin Profitability 0.0% -81.3% Higher Margin CRSP
Return on Equity (ROE) Capital Efficiency -25.6% -929.3% Higher ROE CRSP
52-Week Range Position Momentum 1% ($40โ€“$63) 34% ($1โ€“$3) Stronger Trend PACB
Beta / 30D Volatility Risk Regime 1.85ฮฒ ยท 60% Vol 2.27ฮฒ ยท 112% Vol Lower Realized Risk CRSP
Unified Institutional Score Composite Signal 48.6 / 100 (HOLD) 38.0 / 100 (SELL) Higher Composite CRSP

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CRSP vs PACB Buy Guide
CRSP BREAKDOWN
58d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live CRSP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
PACB BREAKDOWN
12d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 47th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live PACB Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CRSP nor PACB registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.